A new, simple blood test offering a potential early prediction of breast cancer treatment response is poised to dramatically alter how oncologists approach patient care. The test, developed by researchers at the Institute of Cancer Research, London, analyzes circulating tumor DNA (ctDNA) – microscopic cancer DNA released into the bloodstream – and could spare millions of patients from ineffective therapies, accelerating the move towards truly personalized cancer treatment.
- Early Prediction: The test can predict treatment response even *before* a full treatment cycle is completed, potentially after just four weeks.
- Improved Outcomes: Patients with low ctDNA levels before and during treatment demonstrated significantly longer progression-free survival, particularly in aggressive triple-negative breast cancer.
- Personalized Medicine: The test paves the way for faster, more personalized treatment decisions, avoiding ineffective drugs and enabling quicker exploration of alternative options like targeted therapies or clinical trials.
The challenge in breast cancer treatment has always been heterogeneity – the fact that even within the same subtype, cancers respond differently to the same drugs. With over 2 million diagnoses globally each year, and treatment options continually evolving, identifying the *right* treatment for the *right* patient at the *right* time is a critical, and often frustrating, process. Traditional methods rely on tumor biopsies, which are invasive and only provide a snapshot of the cancer at a single point in time. Liquid biopsies, analyzing ctDNA, offer a dynamic, real-time view of the disease, reflecting changes as they occur.
This research builds on a growing body of evidence supporting the utility of ctDNA as a biomarker. The ICR team’s study, involving 167 patients with advanced breast cancer, focused on two key groups: those with specific genetic mutations (ESR1, HER2, AKT1, AKT or PTEN) eligible for targeted therapies, and those with triple-negative breast cancer, a particularly aggressive form lacking clear targetable mutations. The results were striking. For triple-negative patients receiving a combination of olarparib and ceralasertib, those with low ctDNA levels before treatment experienced 10.2 months of progression-free survival compared to just 4.4 months for those with higher levels. Even more compelling, patients whose ctDNA became undetectable after four weeks of treatment saw their cancer kept at bay for 12 months versus 4.3 months for those with persistent detectable ctDNA.
The Forward Look: While the study focused on advanced breast cancer, the potential extends to earlier stages. Professor Nicholas Turner of the ICR suggests the test could be applicable to early-stage disease, allowing for more informed treatment decisions from the outset. However, the immediate next step is validating these findings in larger, multi-center clinical trials. Several trials are already underway to determine if adapting treatment based on ctDNA levels demonstrably improves patient outcomes. We can expect to see a surge in research focused on refining ctDNA analysis techniques, identifying new biomarkers, and developing algorithms to predict treatment response with even greater accuracy. The ultimate goal is a future where liquid biopsies are routinely used to guide breast cancer treatment, minimizing unnecessary toxicity and maximizing the chances of long-term remission. Furthermore, the success of this approach in breast cancer will likely accelerate its adoption in other cancer types, ushering in a new era of precision oncology.
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.
